Drug Trial Radar · NCT06679036
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 21, 2025
Primary completion
Oct 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.
Conditions
- Advanced Unresectable or Metastatic Breast Cancer
Interventions
HRS-2189Drug
HRS-2189
FluvustatDrug
Fluvustat
HRS-8080Drug
HRS-8080
HRS-6209Drug
HRS-6209
HRS-1358Drug
HRS-1358
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEs+SAEsTime frame: From the first drug administration to within 30 days for the last treatment dose.
- Dose limited toxicity (DLT)Time frame: Up to 28 days.
- Maximum tolerated dose (MTD)Time frame: Up to 28 days.
- Recommended Phase II Dose (RP2D)Time frame: Up to 28 days.
- ORR (objective response rate) - Stage II (efficacy expansion)Time frame: Every 8 weeks lasting about one year.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.